Novel Thyroid Hormone Receptor-β Agonist TG68 Exerts Anti-Inflammatory, Lipid-Lowering and Anxiolytic Effects in a High-Fat Diet (HFD) Mouse Model of Obesity DOI Creative Commons
Beatrice Polini,

Caterina Ricardi,

F. Di Lupo

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(8), P. 580 - 580

Published: April 11, 2025

Recent advances in drug development allowed for the identification of THRβ-selective thyromimetic TG68 as a very promising lipid lowering and anti-amyloid agent. In current study, we first investigated neuroprotective effects on vitro human models neuroinflammation β-amyloid neurotoxicity order to expand our knowledge therapeutic potential this novel thyromimetic. Subsequently, examined metabolic inflammatory profiles, along with cognitive changes, using high-fat diet (HFD) mouse model obesity. Our data demonstrated that was able prevent either LPS/TNFα-induced response or β-amyloid-induced cytotoxicity microglial (HMC3) cells. Next, HFD-fed mice, treatment (10 mg/kg/day; 2 weeks) significantly reduced anxiety-like behavior stretch–attend posture (SAP) tests while producing 12% BW loss significant decrease blood glucose levels. Notably, these highlight close relationship between improved serum parameters reduction anxious behavior. Moreover, administration observed efficiently counteract HFD-altered central peripheral expressions mice selected biomarkers dysfunction, inflammation, neurotoxicity, revealing effects. conclusion, work provides preliminary evidence may represent opportunity interlinked diseases such obesity neurodegenerative diseases.

Language: Английский

Differential impacts of high-intensity interval training and moderate-intensity continuous training on obesity-induced behavioral and biochemical dysregulation in male mice DOI

Hossein Nazari,

Ayoob Sabaghi,

Ershad Nedaei

et al.

Sport Sciences for Health, Journal Year: 2025, Volume and Issue: unknown

Published: April 4, 2025

Language: Английский

Citations

0
Novel Thyroid Hormone Receptor-β Agonist TG68 Exerts Anti-Inflammatory, Lipid-Lowering and Anxiolytic Effects in a High-Fat Diet (HFD) Mouse Model of Obesity DOI Creative Commons
Beatrice Polini,

Caterina Ricardi,

F. Di Lupo

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(8), P. 580 - 580

Published: April 11, 2025

Recent advances in drug development allowed for the identification of THRβ-selective thyromimetic TG68 as a very promising lipid lowering and anti-amyloid agent. In current study, we first investigated neuroprotective effects on vitro human models neuroinflammation β-amyloid neurotoxicity order to expand our knowledge therapeutic potential this novel thyromimetic. Subsequently, examined metabolic inflammatory profiles, along with cognitive changes, using high-fat diet (HFD) mouse model obesity. Our data demonstrated that was able prevent either LPS/TNFα-induced response or β-amyloid-induced cytotoxicity microglial (HMC3) cells. Next, HFD-fed mice, treatment (10 mg/kg/day; 2 weeks) significantly reduced anxiety-like behavior stretch–attend posture (SAP) tests while producing 12% BW loss significant decrease blood glucose levels. Notably, these highlight close relationship between improved serum parameters reduction anxious behavior. Moreover, administration observed efficiently counteract HFD-altered central peripheral expressions mice selected biomarkers dysfunction, inflammation, neurotoxicity, revealing effects. conclusion, work provides preliminary evidence may represent opportunity interlinked diseases such obesity neurodegenerative diseases.

Language: Английский

Citations

0